We are Europe's first online investment platform specialized in biotechnology and healthcare.
We connect investors with biotechnology and healthcare companies seeking funding.
Once upon a time... 2015, and the need to connect investors with companies in the biotech sector.
For years, only a few specialists with a lot of money have been able to invest in biotech companies - one of the most profitable sectors in the world.
But why should this type of investment be reserved for these few specialists?
Capital Cell was born to make available to everyone the work of a highly specialized team of professional investors, lawyers, financiers, scientists and health experts from around the world.
You have never had it so easy to invest in the most profitable sector with the greatest social impact.
Together with a global network of science and investment experts, we select the best innovative companies with high profitability potential.
Our value proposition consists of reducing the risk of investing in biotechnology thanks to the in-depth analysis we carry out on companies.
Start of activity: 2015
Operating Headquarters: Barcelona
Founders: Daniel Oliver
Activity license: PFP , license CNMV nº17
Average size of rounds: €880,000
Largest round: €2,000,000
Nice to meet you
We are a team of experts in investment, science and finance.
Technology is our ally - it allows us to offer an efficient and fast service to investors and companies - but we still believe that human relationships are essential when it comes to generating value:
we provide care 100% personalizedto both investors and companies.
Teodor De Mas
Chief Investment Officer
Analyst & Campaign Manager
Regulatory and Market Access
Board of directors and advisors
We are convinced that we are backed by the best.
They are all deeply involved in the company's management and decision-making processes, and the operations of Capital Cell benefit daily from their participation.
Jordi is an entrepreneur, investor and advisor. He was part of the Center for Genomic Regulation in Barcelona, where he worked with TBDO identifying investment opportunities in the biotech market. He brings to Capital Cell both his knowledge and passion for biotechnology and his know-how in the creation of a successful company, from its foundation to its sale.
Nigel has a long track record in biotech startups. He is on the board of 12 companies, 7 of which he founded. He is founder of Athena Diagnostics, sold for $740 million, professor at Harvard Medical School and ESADE Barcelona and co-inventor of 8 patents.
Xavier holds an MBA from ESADE Barcelona and has extensive experience managing companies specialized in the banking and investment sector, from their accelerated growth phase to their IPO. He is a member of the board of directors of several technology and scientific companies.
Joan is a Senior Software Developer with extensive experience in analysis, design, development and implementation of various internet applications and Blockchain expert. He has founded, managed and successfully sold two Engineering companies. He leads the vision and technology development at Capital Cell.